Page 9 - Pascal Deschatelets News Today

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) have been given a consensus recommendation of “Moderate Buy” by the fifteen brokerages that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, seven have assigned a buy recommendation and one has issued […]

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) shares hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $80.77 and last traded at $80.03, with a volume of 124231 shares. The stock had previously closed at $79.65. Wall Street Analyst Weigh In APLS has been the topic of […]

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) insider Pascal Deschatelets sold 12,000 shares of the stock in a transaction on Monday, April 10th. The shares were sold at an average price of $78.21, for a total transaction of $938,520.00. Following the sale, the insider now directly owns 1,027,313 shares of the company’s stock, valued at […]

Dupont Capital Management Corp boosted its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) by 139.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 15,177 shares of the company’s stock after acquiring an additional 8,833 shares during the […]

NJ State Employees Deferred Compensation Plan acquired a new position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 6,000 shares of the company’s stock, valued at approximately $310,000. Several other hedge funds have also […]

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) CEO Cedric Francois sold 30,000 shares of the company’s stock in a transaction dated Tuesday, March 21st. The shares were sold at an average price of $62.74, for a total transaction of $1,882,200.00. Following the completion of the transaction, the chief executive officer now directly owns 1,144,591 shares […]

Amalgamated Bank raised its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) by 5.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,172 shares of the company’s stock after acquiring an additional 772 shares during the period. Amalgamated Bank’s […]

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating)’s stock price was up 3.1% during mid-day trading on Thursday . The company traded as high as $42.46 and last traded at $42.45. Approximately 19,657 shares traded hands during trading, a decline of 98% from the average daily volume of 1,062,128 shares. The stock had previously closed at […]

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) Director Alec Machiels sold 1,250 shares of Apellis Pharmaceuticals stock in a transaction dated Tuesday, March 15th. The stock was sold at an average price of $39.57, for a total transaction of $49,462.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which […]

WEEKEND READ | “These days, everything is so expensive." Many are getting frugal to make ends meet.